group lawmakers call national institute health department health human service step reduce cost medivation inc astellas pharma inc prostate cancer drug xtandi letter sign democratic u.s. presidential candidate bernie sanders reps. lloyd doggett d-texas peter welch d-vt. lawmakers urge nih hold public hear consider override patent xtandi make drug available low price medication average wholesale price unite state 129,000 sell japan sweden 39,000 canada 30,000 accord lawmakers letter address hhs secretary sylvia burwell nih director francis collins note federal fund support development drug base research university california los angeles conduct taxpayer-supported grant americans pay research result pharmaceutical drug available reasonable price say doggett co-chair house democratic caucus prescription drug task force unaffordable drug 100 percent ineffective spokesman astellas say 81 percent privately insure patients pay 25 less pocket per month medication 2015 79 percent medicare patients pay nothing pocket eligible patients insurance underinsured annual adjust household income 100,000 less astellas provide xtandi free spokesman tyler marciniak say 20,000 men treat xtandi last year 2,000 receive drug free add prostate cancer one common cancers america affect one seven men accord american cancer society u.s. lawmakers presidential candidates recent months step criticism u.s. drug price trend raise investor concern future price cut could hurt pharmaceutical biotech company unite state government use every tool available low outrageously high prescription drug price sanders say nih power stop blatant profiteer put pharmaceutical industry notice era charge unconscionable price must end medivation could reach comment spokesmen nih hhs could reach also sign letter sens al franken d-minn. sheldon whitehouse d-r.i. amy klobuchar d-minn. patrick leahy d-vt. elizabeth warren d-mass well reps. elijah cummings d-md jan schakowsky d-ill. rosa delauro d-conn. mark pocan d-wis. u.s. lawmakers want health agencies low prostate cancer drug cost